Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Prostate cancer in a transgenic mouse.

Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM.

Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43.

2.

Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.

Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ.

Lab Invest. 1998 Mar;78(3):319-33. Corrected and republished in: Lab Invest. 1998 Jun;78(6):i-xv.

PMID:
9520945
3.

Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.

Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ.

Lab Invest. 1998 Jun;78(6):i-xv.

PMID:
9645768
4.

Human prostate cancer progression models and therapeutic intervention.

Chung LW, Kao C, Sikes RA, Zhau HE.

Hinyokika Kiyo. 1997 Nov;43(11):815-20. Review.

PMID:
9436028
5.

Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.

Hsieh CL, Gardner TA, Miao L, Balian G, Chung LW.

Cancer Gene Ther. 2004 Feb;11(2):148-55.

PMID:
14695756
6.
7.

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW.

Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2).

PMID:
10881018
8.

Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.

Eastham JA, Grafton W, Martin CM, Williams BJ.

J Urol. 2000 Sep;164(3 Pt 1):814-9.

PMID:
10953161
9.

Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.

Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG.

Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6369-74.

10.

Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.

Gabril MY, Onita T, Ji PG, Sakai H, Chan FL, Koropatnick J, Chin JL, Moussa M, Xuan JW.

Gene Ther. 2002 Dec;9(23):1589-99.

11.

A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ.

Cancer Res. 2001 Mar 1;61(5):2239-49.

13.

Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.

Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H.

Cancer Res. 2000 Sep 15;60(18):5125-33.

14.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
15.
16.

Bub1 up-regulation and hyperphosphorylation promote malignant transformation in SV40 tag-induced transgenic mouse models.

Guo C, Wu G, Chin JL, Bauman G, Moussa M, Wang F, Greenberg NM, Taylor SS, Xuan JW.

Mol Cancer Res. 2006 Dec;4(12):957-69.

17.

Elevated expression of inhibitor of apoptosis proteins in prostate cancer.

Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ, Reed JC.

Clin Cancer Res. 2003 Oct 15;9(13):4914-25.

18.

Inactivation of Apc in the mouse prostate causes prostate carcinoma.

Bruxvoort KJ, Charbonneau HM, Giambernardi TA, Goolsby JC, Qian CN, Zylstra CR, Robinson DR, Roy-Burman P, Shaw AK, Buckner-Berghuis BD, Sigler RE, Resau JH, Sullivan R, Bushman W, Williams BO.

Cancer Res. 2007 Mar 15;67(6):2490-6.

19.
Items per page

Supplemental Content

Support Center